Richmond Pharmacology is excited to confirm our attendance at AHA Scientific Sessions 2025, hosted by the American Heart Association in New Orleans from 8–10 November.
Representing Richmond at AHA 2025:
We look forward to connecting with attendees to discuss Richmond’s expertise in:
If you’re attending AHA 2025 and seeking a clinical development partner with cardiovascular expertise, arrange a meeting with us: info@richmondpharmacology.com
Learn more: AHA 2025 | American Heart Association's Scientific Sessions
Richmond Research Institute to present key cardiology research at Heart Failure 2025 in Belgrade, Serbia.
The Pathway study is based on pioneering work during the pandemic between clinicians at Richmond Pharmacology and...
Authored by Georg Ferber, PhD, Dilshat Djumanov, PhD, Ulrike Lorch, MD, FFPM, Edward Jackson, BSc, MSc, PhD, MBChB, Joao Almeida Melo, James Rickard, MPharm, and Jorg Taubel, MD, FFPM, FESC.
RRI Lead Specialty Research Physician wins award for Cardiovascular risk factor analysis of data associated with UK grocery brand Tescos
We studied the cardiac safety of P218 using advanced QTc assessments and found doses of up to 1000mg do not prolong the QTc suggesting a low risk of drug induced arrhythmia.
Here we present the results of our recent work on the cardiac safety of cortexolone 17α-propionate (cortexolone).
12-lead resting ECGs are considered essential in clinical trials, but their limitations have led to increasing use of 12-lead Holter monitor devices.
Here we report our recent work on the cardiac safety of nolasiban.
Findings from our recent study show how cardiac ion channel blocking agents could increase the risk of sudden cardiac death in patients with type 1 diabetes, particularly in women.